Bryan Garnier - Qiagen (QIA) QIAGEN: After a bump in the road, leverage should follow | BUY | EUR39 vs. EUR36.5 (+13%)

Report

Bryan Garnier

Hugo Solvet

QIAGEN: After a bump in the road, leverage should follow | BUY | EUR39 vs. EUR36.5 (+13%)

QIAGEN - BUY | EUR39 vs. EUR36.5 (+13%)
After a bump in the road, leverage should follow

End of NGS JV in China will not affect the proprietary portfolio
QIAGEN/DiaSorin partnership for QuantiFERON unfolding nicely
Leverage should follow a strong launch wave
FV up to EUR39 (vs EUR36.5) despite adjustments to CY 19

01/08/2019 3 EN

Underlying

Qiagen

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.36

November 25, 2019 November 25, 2019 14 EN

Bryan Garnier

QIAGEN: QIAGEN could fetch EUR41-44/share in a takeout | BUY | EUR30(-12%)

QIAGEN - BUY | EUR30(-12%) QIAGEN could fetch EUR41-44/share in a takeout QIAGEN worth EUR41-44/share Highly accretive: QIA could bring up to USD260m in synergies Multiple interests could lead to a higher bid

November 19, 2019 November 19, 2019 3 EN

Ebusco: The expert e-bus platform

Following the publication of our industry note entitled "Electrifying the future of on-road HDVs", we initiate coverage of Ebusco with a Buy rating and a price target of EUR5.5.Founded in 2012, Ebusco is a Dutch designer and manufacturer of fully electric transit-buses, both for city or regional us

May 16, 2024 May 16, 2024 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Nikola Corp: The dual e-trucking arm

Following the publication of our industry note entitled "Electrifying the future of on-road HDVs", we initiate coverage of Nikola Corp with a Buy rating and a price target of USD1.0.Founded in 2015, Nikola is a pioneering American designer and manufacturer of ZE HDV class 8 trucks, leveraging both

May 16, 2024 May 16, 2024 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Electrifying the future of on-road HDVs

Road transport accounts for about 75% of transport emissions worldwide and is responsible for around 21% of total emissions. More than a third is directly related to medium and heavy-duty vehicles (MHDV) i.e. buses and trucks, the bulk of which relates to freight.With major economies gradually alig

May 16, 2024 May 16, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QIAGEN: After a bump in the road, leverage should follow | BUY | EUR39 vs. EUR36.5 (+13%)

Monthly LMI Update Independent Investment Research

Feasibility Study Results in December to be a Catalyst for this Junior

QIAGEN: QIAGEN could fetch EUR41-44/share in a takeout | BUY | EUR30(-12%)

Ebusco: The expert e-bus platform

Nikola Corp: The dual e-trucking arm

Electrifying the future of on-road HDVs

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe